BALTIMORE--(BUSINESS WIRE)--The Institute of Human Virology (IHV) at the University of Maryland School of Medicine is hosting the IHV 16th Annual International Meeting Sunday, September 14 through Wednesday, September 17 at the Sheraton Inner Harbor Hotel in Baltimore, Maryland. The Annual Meeting will feature themes on HIV cure research; HIV pathogenesis; HIV structural biology, immunology and vaccines; advances in clinical, prevention and public health research, and a cross-cutting session on the molecular and immunological insights from cancer biology and treatment.
“This year’s meeting will cover some very important issues including developments in HIV cure and vaccine research,” said Robert C. Gallo MD, Director of the Institute of Human Virology and The Homer & Martha Gudelsky Distinguished Professor in Medicine at the University of Maryland School of Medicine. “We also have a session on cancer with some of the top international field investigators – who will address the interface between cancer cure and HIV cure.” Dr. Gallo is most widely known for his co-discovery of HIV as the cause of AIDS and, along with his coworkers, for the development of the HIV blood test.
IHV will present its Lifetime Achievement Awards at a gala on Tuesday evening. William Paul, MD, will be honored as the 2014 IHV Lifetime Achievement Awardee for Scientific Contributions to the field of immunology and pathogenesis. Dr. Paul is Chief of the Laboratory of Immunology at the National Institute of Allergy and Infectious Diseases, and was former director of the National Institutes of Health Office of AIDS Research. He is also the founding editor of the Annual Review of Immunology and a member of the National Academy of Sciences. The 2014 Lifetime Achievement Award for Public Service will be presented to John Martin, PhD. As Gilead’s current Chief Executive Officer and Chairman of the Board, Dr. Martin is a leader in supporting access to life-saving anti-HIV medications that although still under patent have been made widely and affordably available to millions around the world infected with HIV, and for prevention through Pre-exposure drug therapy.
“Bill Paul’s discoveries and research in immunology have impacted biomedical research greatly,” said Dr. Gallo. “And, as head of a pharmaceutical company developing life-saving drugs for HIV infection, John Martin has been a world leader in combating AIDS in developing nations. Both have made tremendous contributions to public health, and we are proud to honor Bill and John, each of whom have contributed so much, and influenced so many, at the Institute.”
In 1996 Dr. Gallo co-founded the IHV with colleagues William Blattner, MD and Robert Redfield, MD. The Baltimore-based Institute treats more than 500,000 HIV positive individuals in 7 African and 2 Caribbean nations in addition to more than 5,000 HIV positive Baltimoreans. IHV is internationally renowned for its basic science research, which includes the search for a functional cure and a promising preventive HIV vaccine candidate funded largely by the Bill & Melinda Gates Foundation and the National Institute of Allergy and Infectious Diseases. For more information visit www.ihv.org and follow us on Twitter @IHVmeeting2014 and #IHVmeeting.